

**TABLE S1** *C. albicans* strains used in this study

Strain	Designation	Strain Background	Relevant characteristics or genotype	Source
SC5314	SC5314	N/A	<i>CAS5/CAS5</i>	ATCC
SCCAS5A5A66C	<i>cas5Δ/Δ</i>	SC5314	<i>cas5Δ::FRT/cas5Δ::FRT</i>	This study
SCCAS5A5A66C1B	<i>cas5Δ/Δ+CAS5</i>	SCCAS5A5A66C	<i>cas5Δ::FRT/CAS5-caSAT1</i>	This study
SCRPN4A1A21C	<i>rpn4Δ/Δ</i>	SC5314	<i>rpn4Δ::FRT/rpn4Δ::FRT</i>	This study
SCRPN4A1A21C6A	<i>rpn4Δ/Δ+RPN4</i>	SCRPN4A1A21C	<i>rpn4Δ::FRT/RPN4-caSAT1</i>	This study
SCCZF1G1D12	<i>czf1Δ/Δ</i>	SC5314	<i>czf1Δ::FRT/czf1Δ::FRT</i>	This study
BWP17	BWP17	RM1000	<i>ura3Δ::λimm434/ ura3Δ::λimm434 his1::hisG/his1::hisG arg4::hisg/arg4::hisG</i>	Wilson, 1999
VIC1186	1186	BWP17	<i>cas5Δ::ARG4/ cas5Δ::URA3 pHIS1::his1::hisG/ his1::hisG</i>	Bruno, 2006
VIC1190	1190	1186	<i>cas5Δ::ARG4/ cas5Δ::URA3 pCAS5::HIS1::his1::hisG/ his1::hisG</i>	Bruno, 2006
Clinical isolate 2-79	2-79	N/A	Susceptible isolate	Redding, 1994
Clinical isolate 12-99	12-99	N/A	Resistant isolate	Redding, 1994
12-99CAS5A1A72	12-99 <i>cas5Δ/Δ</i>	12-99	<i>cas5Δ::FRT/cas5Δ::FRT</i>	This study
G2	G2	G1	Susceptible isolate	Franz, 1998
G5	G5	G2	Resistant isolate	Franz, 1998
G5CAS5B16D3D	G5 <i>cas5Δ/Δ</i>	G5	<i>cas5Δ::FRT/cas5Δ::FRT</i>	This study
Gu2	Gu2	Gu1	Susceptible isolate	Franz, 1999
Gu5	Gu5	Gu2	Resistant isolate	Franz, 1999
Gu5CAS5A23A4A	Gu5 <i>cas5Δ/Δ</i>	Gu5	<i>cas5Δ::FRT/cas5Δ::FRT</i>	This study
S1	S1	N/A	Susceptible isolate	Franz, 1999
S2	S2	S1	Resistant isolate	Franz, 1999
S2CAS5B6C5A	S2 <i>cas5Δ/Δ</i>	S2	<i>cas5Δ::FRT/cas5Δ::FRT</i>	This study
SCUPC2R14A	<i>UPC2<sup>G648D</sup></i>	SC5314	<i>UPC2<sup>G648D</sup>::FRT/ UPC2<sup>G648D</sup>::FRT</i>	Heilmann, 2010
SCUPC2R14ACAS5A5A21Y	<i>UPC2<sup>G648D</sup>cas5Δ/Δ</i>	SCUPC2R14A	<i>UPC2<sup>G648D</sup>::FRT/ UPC2<sup>G648D</sup>::FRT CAS5/CAS5</i>	This study
10C1B1M1	<i>ERG11<sup>K143R</sup></i>	SC5314	<i>ERG11<sup>K143R</sup>::FRT/ ERG11<sup>K143R</sup>::FRT CAS5/CAS5</i>	Vasicek, 2013
10C1B1M1CAS5-1A51B	<i>ERG11<sup>K143R</sup>cas5Δ/Δ</i>	10C1B1M1	<i>ERG11<sup>K143R</sup>::FRT/ ERG11<sup>K143R</sup>::FRT cas5Δ::FRT/cas5Δ::FRT</i>	This study
SCMRR1R34A	<i>MRR1<sup>P683S</sup></i>	SC5314	<i>MRR1<sup>P683S</sup>::FRT/ MRR1<sup>P683S</sup>::FRT CAS5/CAS5</i>	Schubert, 2011

SCMRR1R34ACAS5-2A3	<i>MRR1</i> <sup>P683S</sup> <i>cas5</i> Δ/Δ	SCMRR1R34A	<i>MRR1</i> <sup>P683S</sup> ::FRT/ <i>MRR1</i> <sup>P683S</sup> ::FRT <i>cas5</i> Δ::FRT/ <i>cas5</i> Δ::FRT	This study
SCTAC1R34A	<i>TAC1</i> <sup>G980E</sup>	SC5314	<i>TAC1</i> <sup>G980E</sup> ::FRT/ <i>TAC1</i> <sup>G980E</sup> ::FRT <i>CAS5</i> / <i>CAS5</i> <i>TAC1</i> <sup>G980E</sup> ::FRT/ <i>TAC1</i> <sup>G980E</sup> ::FRT	Sasse, 2011
SCTAC1R34ACAS5-2A1	<i>TAC1</i> <sup>G980E</sup> <i>cas5</i> Δ/Δ	SCTAC1R34A	<i>TAC1</i> <sup>G980E</sup> ::FRT/ <i>TAC1</i> <sup>G980E</sup> ::FRT <i>cas5</i> Δ::FRT/ <i>cas5</i> Δ::FRT	This study

**TABLE S2** Primers used in this study

Method	Primer	Sequence
qRT-PCR	<i>ACT1</i> -F	5'-ACGGTGAAGAAGTTGCTGCTTTAGTT-3'
	<i>ACT1</i> -R	5'-CGTCGTCACCGGCAAAA-3'
	<i>BMR1</i> -F	5'-ACATAAATACTTTGCCCATCCAGAA-3'
	<i>BMR1</i> -R	5'-AAGAGTTGGTTTGTAAATCGGCTAAA-3'
	<i>CDR1</i> -F	5'-ATTCTAAGATGTCGTCGCAAGATG-3'
	<i>CDR1</i> -R	5'-AGTTCTGGCTAAATTCGTAATGTTTTTC-3'
	<i>CDR2</i> -F	5'-TAGTCCATTCAACGGCAACATT-3'
	<i>CDR2</i> -R	5'-CACCCAGTATTTGGCATTGAAA-3'
	<i>CFL4</i> -F	5'-GCAATGGTTGACAGGTTGGAA-3'
	<i>CFL4</i> -R	5'-GCAATGTGACGATGATAAGTGACAA-3'
	<i>ERG11</i> -F	5'-CCCCTATTAATTTTGTTCCTAATTTAC-3'
	<i>ERG11</i> -R	5'-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3'
	<i>ERG26</i> -F	5'-ATTAGAGTGTGCGATGCCATT-3'
	<i>ERG26</i> -R	5'-CGTCGTCGTAGTCGTCAC-3'
	<i>FTR1</i> -F	5'-ATTGTTGTTTCAGTGCTTTTGGC-3'
	<i>FTR1</i> -R	5'-GGTCGGAACCTACCACCCATAGA-3'
	<i>PGA13</i> -F	5'-CTCCGAAGAAGAAGGAAGCGT-3'
	<i>PGA13</i> -R	5'-GGTGAAATCAGTGACGGTGACTT-3'
	<i>PGA31</i> -F	5'-CTTTCCTTTGATGGTCCGACT-3'
	<i>PGA31</i> -R	5'-GGGTCATTGATGTTCTTGGCA-3'
Mutant construction	<i>CAS5</i> -A	5'-TTCAACTTCAAGGT <u>ACCT</u> GTTGATATTCTA-3'
	<i>CAS5</i> -B	5'-CTAACGGT <u>CTCGAG</u> AAATTTTGTGATAGTT-3'
	<i>CAS5</i> -C	5'-ATTGTGGTAAC <u>CCGCGG</u> TAAATCGTAAAGATA-3'
	<i>CAS5</i> -D	5'-GCATATTTAGGAGCT <u>CCTAGT</u> GGTGATTTA-3'
	<i>CAS5</i> -E	5'-GCATACTGCATATTTAG <u>CTCGAG</u> CTAGTGG-3'
	<i>RPN4</i> -A	5'-AGATCAATATAG <u>GGGCC</u> TAAAGGACATCTT-3'
	<i>RPN4</i> -B	5'-GTGTATTATTGG <u>CTCGAG</u> TAAAAGTGTTGT-3'
	<i>RPN4</i> -C	5'-TAGATTTAAT <u>CCGCGG</u> AGCTAAAGAGAATG-3'
	<i>RPN4</i> -D	5'-CTGGTGAAGAGCTCTAAAGTGATATTATTG-3'
	<i>RPN4</i> -E	5'-CTGGTGAAGAACT <u>CGAGAG</u> TGATATTATTG-3'
	<i>CZF1</i> -A	5'-GCAAAATTCAAAGGGCCCGACCTAATTC-3'
	<i>CZF1</i> -B	5'-GTGGTTGTG <u>CTCGAG</u> GAGAGGTATTGG-3'
	<i>CZF1</i> -C	5'-CAATTGAAGCGGCCGCGTTTGGTAGAATC-3'
	<i>CZF1</i> -D	5'-GTCAACTTTT <u>GCCGCGG</u> CACACACGTA-3'

<sup>a</sup> Underlined sequence reflects the introduction of a restriction site sequence.

**Table S3** TF disruptant clones displaying a reduction in FLC MIC in RPMI (48 hr), rescreened in YPD (24 hr)

Clone ID	CGD	orf19 designation	MIC ( $\mu\text{g/ml}$ )		MFC ( $\mu\text{g/ml}$ )	
			RPMI	YPD	RPMI	YPD
SNI152 (WT)	--	--	0.25	0.5	>4	>64
TF3	<i>RPN4</i>	orf19.1069	0.0625	0.25	0.125	32
TF4	--	orf19.1253	SG <sup>a</sup>	0.5	SG	>64
TF33	<i>CAS5</i>	orf19.4670	0.125	0.25	4	2
TF45	<i>GALA</i>	orf19.5338	0.125	0.5	>4	>64
TF59	<i>ACE2</i>	orf19.6124	0.03125	0.5	2	>64
TF77	<i>UPC2</i>	orf19.391	0.03125	0.125	1	1
TF82	<i>STP4</i>	orf19.909	0.125	0.5	>4	>64
TF95	<i>NDT80</i>	orf19.2119	0.03125	0.5	>4	>64
TF103	<i>HFL1</i>	orf19.3063	NG <sup>a</sup>	NG	NG	NG
TF104	<i>CZF1</i>	orf19.3127	0.0625	0.5	0.25	8
TF126	<i>RIM101</i>	orf19.7247	0.0625	0.5	>4	4
TF127	<i>ISW2</i>	orf19.7401	0.0625	0.25	>4	16
TF155	<i>DAL81</i>	orf19.3252	0.0625	0.5	4	>64
TF158	<i>RAP1</i>	orf19.1773	0.03125	0.5	>4	>64
TF159	--	orf19.1757	0.03125	0.5	>4	>64
TF160	--	orf19.2743	0.03125	0.5	>4	>64
TF163	<i>RFX1</i>	orf19.3865	0.0078125	0.25	>4	>64
TF164	<i>RGT1</i>	orf19.2747	0.0625	0.5	>4	>64
TF165	<i>PPR1</i>	orf19.3986	0.03125	0.25	>4	>64

<sup>a</sup> Abbreviations: Slow growth (SG), No growth (NG)